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Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with
no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumo-
nias. With a median survival of 3e5 years following diagnosis, IPF is characterized by a progres-
sive decline in lung function and quality of life in most patients. Vigilance among clinicians in
recognizing IPF early in the disease course remains critical to properly caring for these pa-
tients, as this provides the widest range of management options. When IPF is suspected, a
multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise
should occur, as this improves diagnostic agreement in both community and academic settings.
When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center
should be considered. ILD center referral may also provide access specialized care, including
clinical trials and lung transplantation, and should be considered for any patient with an estab-
lished diagnosis of IPF.
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The interstitial lung diseases (ILDs) are a heterogeneous
group of diffuse parenchymal lung disorders with similar
clinical, radiographic, physiologic or pathologic features
[1]. ILDs include disorders of known cause, and those with
unknown etiology, referred to as the idiopathic interstitial
pneumonias (IIPs) [2]. The most common and deadly of the
IIPs is idiopathic pulmonary fibrosis (IPF) [3], defined as a
specific form of chronic, progressive fibrosing interstitial
pneumonia of unknown cause, occurring primarily in older
adults, and limited to the lungs [4]. IPF has a median sur-
vival time of 3e5 years after diagnosis, and is characterized
by progressive decline in lung function and quality of life in
most patients [3,5e7]. Despite an evolving understanding
of the underlying disease process, the pathogenesis of IPF
remains unknown.Epidemiology
The global prevalence of IPF is difficult to establish and
reflects the diagnostic complexity of the disease and the
substantial resources needed to establish the diagnosis.
These issues, along with heterogeneity in study design and
case finding methodology, have resulted in variable epide-
miologic data over the last several decades [4,8]. Two
recent population studies in the US reported an IPF inci-
dence of 6.8e8.8 and 16.3e17.4 cases per 100,000 person
years using narrow and broad case definitions, respectively.
These studies found the prevalence of IPF to be 14.0e27.9
(narrow case definitions) and 42.7e63.0 (broad case defi-
nitions) per 100,000 persons [9,10]. Recent epidemiologic
studies from the UK demonstrate that the incidence of IPF
has been rising over the last decade [11,12]. IPF has been
described in all ethnic groups and in both rural and urban
settings [7,13]. Affecting males predominantly, most cases
are diagnosed after age 60 and incidence increases with
age. [7,9e12].Early diagnosis
Evolution of the diagnostic criteria for IPF has resulted in
abandonment of the major and minor criteria set by the
2000 ATS/ERS consensus statement [14]. The latest inter-
national guidelines require exclusion of other known causes
of ILD and the presence of a usual interstitial pneumonia
(UIP) pattern on high-resolution computed tomography
(HRCT) in patients for whom a surgical lung biopsy (SLB) has
not been performed. In patients failing to demonstrate a
typical UIP pattern on HRCT, IPF may still be diagnosed
based on specific combinations of HRCT and SLB patterns
(Table 1) [4]. This diagnostic complexity makes misdiag-
nosis and delayed diagnosis common [15]. A recent survey
showed that a majority of patients with IPF reported seeing
several physicians, and waiting over a year, before
receiving the correct diagnosis [16]. Careful attention to
historical clues, physical exam and other diagnostics can
help establish the diagnosis early and provide those with
IPF the full breadth of options available to them.
History
Any adult over age 50 presenting with unexplained dyspnea
on exertion and cough should prompt consideration of IPF
[4]. Dyspnea in this disease tends to arise insidiously, often
over 6 months or more, and progresses steadily [17]. Over
80% of patients report a non-productive, often intractable
cough that can be debilitating and refractory to antitussive
medications [18e20]. Chest pain is uncommon in IPF and
because the disease is limited to the lungs, the presence of
systemic inflammatory symptoms, including fever, rash,
weight loss, myalgia or arthralgia, makes IPF unlikely and
should prompt consideration of an alternative diagnosis.
Cigarette smoking has been strongly linked to IPF,
especially in those with greater than 20 pack-year history
[21e23]. Hiatal hernia and gastroesophageal reflux disease
(GERD) have also been linked to IPF [24e26]. Environmental
and industrial exposures associated with IPF include
Table 1 Combination of HRCT and surgical lung biopsy for the diagnosis of IPF4.
HRCT patterna Surgical lung biopsy patterna
(when performed)
Diagnosis of IPF?c
UIP UIP
Probable UIP
Possible UIP
Nonclassifiable fibrosisb
YES
Not UIP No
Possible UIP UIP
Probable UIP
YES
Possible UIP
Nonclassifiable fibrosis
Probabled
Not UIP No
Inconsistent with UIP UIP Possibled
Probable UIP
Possible UIP
Nonclassifiable fibrosis
Not UIP
No
Definition of abbreviations: HRCTZ high-resolution computed tomography; IPFZ idiopathic pulmonary fibrosis; UIPZ usual interstitial
pneumonia.
Bold type indicates combinations of HRCT and surgical lung biopsy patterns that correspond with a diagnosis of IPF (a YES in the far right
column). The combination of UIP HRCT and probable UIP or possible UIP or Nonclassifiable fibrosis (surgical lung biopsy patterns) (for
example) equals a diagnosis of IPF; the combination of UIP HRCT and Not UIP (surgical lung biopsy pattern) does not make the diagnosis
of IPF.
a Patterns as described in Table 2B and Fig. 3.
b Nonclassifiable fibrosis: Some biopsies may reveal a pattern of fibrosis that does not meet the above criteria for UIP pattern and the
other idiopathic interstitial pneumonias. These biopsies may be termed ‘‘nonclassifiable fibrosis.’’
c The accuracy of the diagnosis of IPF increases with multidisciplinary discussion. This is particularly relevant in cases in which the
radiologic and histopathologic patterns are discordant (e.g., HRCT is inconsistent with UIP and histopathology is UIP). There are data to
suggest that the accuracy of diagnosis is improved with multidisciplinary discussion among interstitial lung disease experts compared to
clinician-specialists in the community setting; timely referral to interstitial lung disease experts is encouraged.
d Multidisciplinary discussion should include discussions of the potential for sampling error and a re-evaluation of adequacy of tech-
nique of HRCT. NOTE: In cases with an ‘‘inconsistent with UIP’’ HRCT pattern and a ‘‘UIP’’ surgical lung biopsy pattern, the possibility of
a diagnosis of IPF still exists and clarification by multidisciplinary discussion among interstitial lung disease experts is indicated.
Reprinted from Ref. [4] with permission of the American Thoracic Society. Copyright ª 2014 American Thoracic Society.
Idiopathic pulmonary fibrosis 821pesticide, metal, wood, vegetable, and animal dust expo-
sure, as well as professions in petrochemical, farming,
hairdressing and stone cutting/polishing [23,27e30]. A
family history of pulmonary fibrosis or ILD should prompt
consideration of familial interstitial pneumonia (FIP). Fa-
milial disease was originally thought to account for fewer
than 5% of IPF cases, but recent studies suggest this esti-
mate may be low [16,31,32].Figure 1 Chest radiograph of a patient with IPF. Findings
include asymmetric peripheral and basilar reticular opacity
and lower lobe volume loss.Physical exam
On exam, patients with IPF generally exhibit inspiratory
crackles, a finding reported in over 90% of patients [33,34].
These fine, Velcro-like crackles may be the earliest clinical
finding in IPF and some authors suggest that auscultation of
crackles is the best test for identifying early disease due to
their excellent sensitivity and good specificity for IPF
[35,36]. An extremity exam should be conducted in every
patient with suspected IPF as 25e50% of patients will
display finger clubbing [33,34,37]. Signs of connective tis-
sue disease including joint deformity, synovitis, muscle
weakness and rash make IPF unlikely and should prompt
further investigation into rheumatologic disease.
Figure 2 HRCT of the chest demonstrating classic UIP pattern. Findings include peripheral and basilar predominant reticulation
with traction bronchiectasis and honeycombing.
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Common laboratory assays generally provide little help in
identifying patients with IPF but serologic testing should be
performed to exclude underlying connective tissue disease
[4]. Up to 20% of patients with IPF have a positive autoan-
tibody but no other signs of connective tissue disease,
which is of unclear clinical significance as healthy controls
demonstrate a similar autoantibody frequency [38]. Several
biomarkers have been linked to accelerated mortality in IPF
[39,40] and substantial research is ongoing to identify
unique gene signatures [41] that may serve as diagnostic
and prognostic tools in the future.
Pulmonary function testing
Pulmonary function testing usually demonstrates a restric-
tive pulmonary defect, defined as a reduction in total lung
capacity (TLC). Most patients with IPF will also exhibit a
decreased forced vital capacity (FVC), normal-to-increased
forced expiratory volume in 1 s to forced vital capacityTable 2 HRCT specifications and findings in IPF.
A)
Specifications for Performing HRCTa
 High spatial frequency reconstruction algorithm
 Thin slices (2 mm for non-helical CT, 1.5 mm for helical CT
B)
HRCT findings in IPFb
Usual Interstitial Pneumonia (UIP)
 Subpleural, basal predominance
 Reticular abnormality
 Honeycombing (  traction bronchiectasis)
 Absence of features inconsistent with UIP
Possible UIP
 Features of UIP without honeycombing
a Specifications for performing HRCT adapted from Ref. [55].
b HRCT findings in IPF adapted from Ref. [4].(FEV1/FVC) ratio and reduced diffusing capacity of carbon
monoxide (DLCO) [7,42]. A normal FVC does not exclude IPF,
as this can be near normal early in the disease course [43].
Furthermore, patients with concurrent emphysema may
manifest normal lung volumes and spirometry, but will
generally have a reduced DLCO [44,45]. Low baseline FVC,
decline in FVC, low DLCO and decline in 6-min walk test are
associated with decreased survival in IPF [46e50].
Chest radiograph
Patients with IPF tend to demonstrate an asymmetric pe-
ripheral, basilar reticular opacity with lower lobe volume
loss on chest radiograph (Fig. 1) [51e53]. The low sensi-
tivity for detecting subtle interstitial changes can result in
a normal chest radiograph in some patients with IPF
[37,54]. The presence of airspace filling opacities makes IPF
unlikely and should prompt investigation into an alternative
diagnosis. While the chest radiograph may identify IPF, it
does not provide a high degree of confidence and therefore
is not used in the diagnostic criteria [4,53]. Non-intravenous (IV) contrast enhanced
)  Includes supine/prone positioning
 Includes inspiratory/expiratory images
Inconsistent with UIP
 Upper or mid-lung predominance
 Peribronchovascular predominance
 Ground glass pattern predominant
 Profuse micronodules
 Discrete cysts (separate from honeycombing)
 Diffuse mosaic attenuation
 Segmental/lobar consolidations
Figure 3 Histopathologic UIP pattern. Low-power photomicrographs showing findings characteristic of UIP, including subpleural
interstitial fibrosis (thin arrow) with temporal heterogeneity (normal lung at the lower right of each slide) and fibroblastic foci
(thick arrow). (Courtesy of Aliya Husain, M.D., Department of Pathology, The University of Chicago).
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A high-resolution computed tomography (HRCT) of the
chest should be performed in any patient with an abnormal
chest radiograph and clinical findings suggestive of IPF or
another ILD.
HRCT, which provides excellent specificity for IPF in the
appropriate clinical setting, can be used to diagnose IPF in
the majority of cases [55e59]. Patients with IPF generally
demonstrate a pattern of usual interstitial pneumonia (UIP)
on HRCT, which is characterized by a subpleural, basilar
predominant reticular abnormality with honeycombing and
often traction bronchiectasis (Fig. 2). Features of UIP,
possible UIP and those inconsistent with UIP are summa-
rized in Table 2A. Due to institutional variability in ordering
and performing HRCT, pre-test discussion with a radiologist
should occur to ensure the appropriate ILD protocol is fol-
lowed. The necessary components of HRCT, as recom-
mended by the American College of Radiology [60], are
summarized in Table 2B. Adhering to these guidelines helps
avoid repeat imaging and radiation exposure.
Bronchoscopy
While bronchoalveolar lavage (BAL) may assist in diagnosing
inflammatory disorders such as hypersensitivity pneumo-
nitis or eosinophilic pneumonia, it provides little help in
identifying patients with IPF [7,61]. The same is true of
transbronchial biopsy. Raghu and colleagues reported that
85% of patients undergoing surgical lung biopsy (SLB) priorTable 3 Interobserver agreement k score stratified by center t
Step Clinicians Radiologist
Academic Community Academic
1 0.28 (0.03) 0.20 (0.07) 0.59 (0.11)
2 0.32 (0.03) 0.23 (0.06) 0.41 (0.08)
3 0.37 (0.02) 0.27 (0.06) 0.45 (0.08)
4 0.62 (0.03) 0.47 (0.08) 0.55 (0.08)
5 0.71 (0.03) 0.44 (0.07) 0.55 (0.08)
Definition of abbreviation: NA Z not available.
Values are k scores (SE).
Reprinted from Ref. [69] with permission of the American Thoracic Sto referral for ILD evaluation had undergone a non-
diagnostic transbronchial biopsy [57]. Accordingly, the lat-
est international guidelines for diagnosis and management
of IPF recommend against performing a BAL or trans-
bronchial biopsy in the majority of patients in whom IPF is
suspected [4].
Surgical lung biopsy
The decision to pursue a SLB requires substantial risk/
benefit consideration and should occur only after a
comprehensive ILD evaluation. This highly morbid proce-
dure has several known complications, including persistent
air leak, prolonged mechanical ventilation, pneumonia and
acute exacerbation of IPF. A mortality rate of 4e16% was
reported in two case series of patients with ILD undergoing
SLB; however, a substantial proportion of these were open
lung biopsies and more recent data suggest video-assisted
thorascopic surgery (VATS) biopsy may be safer [62e64]. In
these studies, male gender and low DLCO were risk factors
for SLB-associated complications, while low DLCO and acute
exacerbation at the time of biopsy were independently
associated with increased 30-day mortality [62,63].
In those with an indication for SLB, pre-biopsy discussion
with the thoracic surgeon should occur to ensure each lobe
of a single lung is biopsied when possible, as considerable
histologic variability between lobes can occur [65].
Furthermore, care should be taken to biopsy less diseased
lung preferentially so as to enhance the pulmonary pa-
thologist’s ability to survey areas undergoing active fibrosis.ype and step of the evaluation process.
s Pathologists
Community Academic Community
0.38 (0.12) 0.57 (0.06) 0.14 (0.17)
0.34 (0.11) NA NA
0.40 (0.11) 0.53 (0.06) NA
0.31 (0.11) 0.53 (0.05) 0.14 (0.15)
0.32 (0.11) 0.57 (0.05) 0.41 (0.13)
ociety. Copyright ª 2014 American Thoracic Society.
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Figure 4 Survival from the time of evaluation at a tertiary
care center adjusted for age and FVC across quartiles of delay.
Entry time into the cohort began at study enrollment.
Reprinted from Ref. [72] with permission of the American
Thoracic Society. Copyright ª 2014 American Thoracic Society.
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UIP pattern, characterized by areas of fibrosis with scarring
and honeycomb change alternating with areas of less
affected or normal parenchyma. This occurs in a predomi-
nant subpleural and paraseptal distribution with little
inflammation and includes subepithelial foci of prolifer-
ating fibroblasts and myofibroblasts known as fibroblastic
foci (Fig. 3) [66]. Like HRCT, varying levels of confidence in
this pathologic diagnosis exist and a small minority of pa-
tients may demonstrate an unclassifiable fibrotic pattern.
Multidisciplinary evaluation
Because non-IPF ILD tends to follow a more favorable
clinical course than IPF, and may respond to corticosteroid
and immunosuppressive therapy [3,67], both of which are
strongly recommended against in IPF [4,68], establishing an
accurate diagnosis is paramount. The 2011 ATS/ERS/JRS/
ALAT consensus statement on the diagnosis of IPF strongly
recommends a multidisciplinary evaluation (MDE) in
establishing the diagnosis [4]. The importance of such
evaluation is highlighted by observations that isolated
radiographic or histologic UIP can represent processes other
than IPF and that IPF does not always demonstrate radio-
graphic or histologic UIP [55,56,69]. MDE should include a
clinician, radiologist and pathologist with considerable IPF
and ILD experience. Discussion among these specialists
leads to improved diagnostic agreement [70], and has
become a cornerstone of evaluation at ILD referral centers.
Whether ILD is best diagnosed in a community or aca-
demic setting remains controversial. Flaherty and col-
leagues conducted an investigation of clinicians, radiologists
and pathologists from community and academic settings to
determine the level of diagnostic agreement in evaluating
ILD [71]. Using a stepwise approach that provided an
increasing amount of clinical, radiographic and histopatho-
logic information, the authors demonstrated that diagnostic
agreement, as determined by kappa score (<0 indicating
poor agreement, 0e0.2 slight agreement, 0.2e0.4 fair
agreement, 0.4e0.6 moderate agreement, 0.6e0.8 sub-
stantial agreement and >0.8 almost perfect agreement),
increased in both groups with each step (Table 3). Though
greater interobserver agreement was demonstrated among
academic physicians compared with those from the com-
munity, considerable disagreement remained within both
groups upon final diagnosis. The authors noted that the
greater agreement among academic than community phy-
sicians was likely influenced by the fact that these in-
dividuals had collaborated on previous projects, including
consensus statements, and that the community clinician
with the most ILD experience tended to agree more often
with the academicians. This study highlights the importance
of MDE and experience in diagnosing ILD, but also un-
derscores the need to improve the means by which we
establish the diagnosis.
Early referral
We recommend early referral to an ILD specialty center
when MDE cannot be performed locally, or when diagnostic
doubt exists following community MDE. Referral has theadded advantage of providing patients access to specialized
care, including clinical trial enrollment and lung transplant
evaluation. Whether referral of patients to an ILD center
improves outcomes is unknown, however, and remains an
area ripe for further investigation. In 2011, Lamas and
colleagues [72] conducted an investigation of 129 patients
with IPF referred to a single ILD center to explore the as-
sociation between time to referral and mortality. The au-
thors showed that the median time from patient-reported
onset of dyspnea to ILD center evaluation was 2.2 years and
that a longer delay was associated with increased risk of
death independent of disease severity (Fig. 4). Determining
the cause of this observed difference was not possible by
nature of the study design and warrants further investiga-
tion. Notably, referral delay did not affect the likelihood of
receiving a lung transplant. The authors acknowledged that
lead-time bias was a potential limitation to this study, but
noted that age and disease severity were similar across
quartiles and that adjusting for these potential confounders
did not significantly alter their results.
When referral cannot be made due to inconvenience or
other factors, local clinicians should screen for comor-
bidities and supplemental oxygen need, along with placing
a referral to pulmonary rehabilitation (PR) for patients
with IPF. In those who are referred, ILD centers provide
additional benefits beyond routine care and therapeutics,
including disease education and support group informa-
tion. Several of these factors were cited among patients
with IPF in a recent qualitative survey as reason for
greater satisfaction when receiving care at an ILD center
compared to a community setting [15]. A review of the
core elements of IPF management at ILD referral centers
is outlined below.
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Patients with IPF are at increased risk for a host of
comorbidities, including pulmonary malignancy [73], coro-
nary artery disease [74], obstructive sleep apnea (OSA)
[75], emphysema [76], pulmonary hypertension [77], dia-
betes mellitus [22], depression [78], hiatal hernia [26], and
GERD [24]. These conditions have the potential to impact
survival and quality of life, and it has therefore become
common practice to manage comorbidities aggressively at
many ILD centers. Though the effectiveness of this
approach in modulating disease course is unknown, Lee and
colleagues showed that the use of GERD therapy indepen-
dently predicted longer survival in patients with IPF, while
Mermigkis and colleagues demonstrated that patients
treated for concurrent OSA reported improved quality of
life. [79,80] An exception to this practice is in patients with
IPF and pulmonary hypertension, as large clinical trials
using pulmonary hypertension therapy have failed to show
efficacy in patients with IPF [81,82]. Finally, it is important
to prevent further morbidity by ensuring patients have
received age-appropriate vaccinations, including those for
influenza and pneumococcus.
Oxygen therapy
Hypoxemia at rest, with sleep and/or with exertion is
common in patients with IPF. Though treatment of resting
hypoxemia with supplemental oxygen has not been studied
in a controlled fashion, the practice received a strong
recommendation in the 2011 ATS/ERS/JRS/ALAT treatment
guidelines [4]. This was partly due to robust evidence in
patients with chronic obstructive lung disease, where a
clear survival benefit was demonstrated with the use of
long-term oxygen [83]. The need for supplemental oxygen
when traveling by air or to altitude should also be assessed
in this population.
Pulmonary rehabilitation
A mainstay of non-pharmacologic therapy for patients with
IPF is PR. A systematic review performed by Holland and
Hill showed that exercise training in patients with ILD,
including IPF, was associated with an improvement in 6-
min walk distance and increased quality of life scores [84].
Many PR programs also include educational components
that teach breathing techniques and dyspnea coping stra-
tegies. As the benefits of PR appear to be most pronounced
early in the disease course, this therapy should be offered
to all patients at the time of diagnosis [85]. In patients who
travel a considerable distance for evaluation, identifying a
PR program close to home can add convenience and
potentially improve adherence.
Pharmacotherapy
Unlike many other forms of ILD and IIP, IPF does not respond
to, and should not be treated with, corticosteroid therapy
[4,34,86]. A similar conclusion has now been reached with
combination prednisone, azathioprine and N-acetylcysteine
(NAC) after early termination of this arm in the PANTHER-IPF trial due to increased mortality and hospitalization
risk compared to placebo [68]. The NAC and placebo arms
of this trial are ongoing to investigate whether NAC leads to
a smaller decline in lung function in patients with IPF, as
suggested by previous studies [87,88].
The use of pirfenidone, an oral antifibrotic agent, in the
treatment of IPF has been evaluated in two Japanese and
two combined North American and European phase III trials
[89e91]. These trials produced discordant results, but a
meta-analysis showed that pirfenidone might slow disease
progression and rate of FVC decline. [92] These results have
supported the approval of pirfenidone in several countries
and regions, including the European Union, Canada, India
and Japan. The US Food and Drug Administration has yet to
approve pirfenidone, pending the results of an ongoing
large phase III U.S. multicenter clinical trial (ASCEND trial,
NCT0136629). Dermatologic (photosensitivity and rash),
neurologic (dizziness and fatigue) and gastro-intestinal
(nausea, dyspepsia, diarrhea and anorexia) side effects
have been reported with pirfenidone and should be
routinely addressed [90,93].
While antifibrotic agents hold promise in treating IPF,
the recently published ACE-IPF study has likely put to rest
the question of warfarin therapy for IPF. This trial stemmed
from a small open-label study showing mortality benefit in
patients treated with anticoagulation in addition to corti-
costeroids [94], but was terminated early due to a low
probability of benefit and increased mortality in the
warfarin arm compared to placebo [95]. Some authors
argue that biologic plausibility still supports targeting the
coagulation cascade, and that heparins, including inhaled
heparin, may be a better choice of anticoagulant and
warrant further investigation [96,97].
Numerous other phase II and III clinical trials are ongoing
or recently completed and may provide additional treat-
ment options in the near future. Information regarding
clinical trial enrollment is provided to patients who qualify
upon evaluation at ILD referral centers. While the decision
to enroll in an IPF clinical trial must be weighed heavily by
patient and physician, clinical trial availability has been
shown to improve patient satisfaction [15], and should be
available to as many patients as possible. Diagnostic and
referral delays can result in clinical trial ineligibility due to
advanced disease, underscoring the importance of active
community physician involvement in this process.Lung transplantation
Lung transplantation remains the sole therapy proven to
prolong survival in IPF [98]. The first lung transplant for IPF
was performed in 1983 [99], and IPF is now the leading
cause of lung transplantation in the US, accounting for 38%
of adult lung transplants in 2012 [100]. Following the
introduction of the Lung Allocation Score (LAS), which pri-
oritizes transplant candidates based on their probability of
survival, there has been a drastic decrease in wait list time
for patients with IPF, from a median of 997 days in 2002 to
2004 to 73 days in May 2005 to December 2007 [101]. Both
single (SLT) and double lung transplants (DLT) are per-
formed for IPF and while SLT is performed more commonly,
the number of DLT procedures continues to rise. [102] This
826 J.M. Oldham, I. Notharea remains controversial as studies show discordant re-
sults in long-term survival advantage between the pro-
cedures [103e107]. International societies including the
American Thoracic Society and International Society for
Heart and Lung Transplantation (ISHLT) strongly recom-
mend early consideration of lung transplantation for pa-
tients with IPF [4,108].
Conclusion
Our understanding of IPF has grown immensely over the last
two decades, yet the diagnostic process remains complex
and misdiagnosis carries grave implications. Attention to
common signs and symptoms, along with proper utilization
of diagnostic tests can help diagnose IPF early in the dis-
ease course. A multidisciplinary approach in both academic
and community settings is equally important in establishing
the diagnosis. Referral to an ILD center should be consid-
ered in all patients with IPF to assist with diagnosis and/or
provide access to the specialized care outlined above. Pa-
tients deserve the opportunity to participate in clinical
trials and to be considered for lung transplant before
advanced disease precludes eligibility, and underscores the
importance of active clinician involvement in this process.
Conflict of interest statement
Dr. Noth has received honoraria for advisory boards with
Boehringer Ingelheim, InterMune, Anthera within the last
12 months related to IPF. He has also received speaking
honoraria from GSK and receives consulting fees for
Immuneworks. He also has study contracts with the NIH,
Stromedix, Sanofi, and Boehringer Ingelheim for the
conduct of clinical trials in IPF. Boehringer Ingelheim
Pharmaceuticals, Inc. paid the processing charge for this
article and was allowed to review the manuscript for
factual accuracy with no editorial input.
Acknowledgments
We thank Dr. Aliya Husain who contributed pathology im-
ages for this review. Medical writing assistance, supported
financially by Boehringer Ingelheim Pharmaceuticals, Inc,
was provided by Clare Ryles and Wendy Morris of Fleishman-
Hillard Group, Ltd during the preparation of this manu-
script. The authors drafted the article, were fully respon-
sible for all content and editorial decisions, were involved
at all stages of manuscript development, and have
approved the final version of the review, which solely re-
flects the authors’ interpretation and conclusions.
References
[1] King Jr TE. Clinical advances in the diagnosis and therapy of
the interstitial lung diseases. Am J Respir Crit Care Med 2005;
172:268e79.
[2] American Thoracic Society/European Respiratory Society In-
ternational Multidisciplinary Consensus Classification of the
Idiopathic Interstitial Pneumonias. This joint statement of
the American Thoracic Society (ATS), and the EuropeanRespiratory Society (ERS) was adopted by the ATS board of
directors, June 2001 and by the ERS Executive Committee,
June 2001. Am J Respir Crit Care Med 2002;165:277e304.
[3] Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance
of histopathologic subsets in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 1998;157:199e203.
[4] Raghu G, Collard HR, Egan JJ, et al. An official
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:
evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med 2011;183:788e824.
[5] De Vries J, Kessels BL, Drent M. Quality of life of idiopathic
pulmonary fibrosis patients. Eur Respir J 2001;17:954e61.
[6] Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-
related quality of life in patients with idiopathic pulmonary
fibrosisecross-sectional and longitudinal study. Intern Med
2007;46:1533e42.
[7] Nathan SD, Shlobin OA, Weir N, et al. Long-term course and
prognosis of idiopathic pulmonary fibrosis in the new mil-
lennium. Chest 2011;140:221e9.
[8] Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and
prevalence of idiopathic pulmonary fibrosis: review of the
literature. Eur Respir Rev 2012;21:355e61.
[9] Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Inci-
dence, prevalence, and clinical course of idiopathic pulmo-
nary fibrosis: a population-based study. Chest 2010;137:
129e37.
[10] Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G.
Incidence and prevalence of idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2006;174:810e6.
[11] Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ.
Incidence and mortality of idiopathic pulmonary fibrosis and
sarcoidosis in the UK. Thorax 2006;61:980e5.
[12] Navaratnam V, Fleming KM, West J, et al. The rising inci-
dence of idiopathic pulmonary fibrosis in the U.K. Thorax
2011;66:462e7.
[13] Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM,
Coultas DB. Idiopathic pulmonary fibrosis: survival in popu-
lation based and hospital based cohorts. Thorax 1998;53:
469e76.
[14] Raghu G. Idiopathic pulmonary fibrosis: guidelines for diag-
nosis and clinical management have advanced from
consensus-based in 2000 to evidence-based in 2011. Eur
Respir J 2011;37:743e6.
[15] Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic
pulmonary fibrosis: an in-depth qualitative survey of Euro-
pean patients. Chron Respir Dis 2011;8:225e31.
[16] Collard HR, Tino G, Noble PW, et al. Patient experiences with
pulmonary fibrosis. Respir Med 2007;101:1350e4.
[17] American Thoracic Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment. International consensus statement.
American Thoracic Society (ATS), and the European Respi-
ratory Society (ERS). Am J Respir Crit Care Med 2000;161:
646e64.
[18] Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR,
Reynolds HY. Idiopathic pulmonary fibrosis. Clinical, histo-
logic, radiographic, physiologic, scintigraphic, cytologic, and
biochemical aspects. Ann Intern Med 1976;85:769e88.
[19] Fioret D, Perez RL, Roman J. Management of idiopathic
pulmonary fibrosis. Am J Med Sci 2011;341:450e3.
[20] Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective
cough frequency in idiopathic pulmonary fibrosis. Cough
2010;6:4.
[21] Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA.
Cigarette smoking: a risk factor for idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 1997;155:242e8.
[22] Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. Diabetes
mellitus may increase risk for idiopathic pulmonary fibrosis.
Chest 2003;123:2007e11.
Idiopathic pulmonary fibrosis 827[23] Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an
environmental disease? Proc Am Thorac Soc 2006;3:293e8.
[24] Raghu G, Freudenberger TD, Yang S, et al. High prevalence of
abnormal acid gastro-oesophageal reflux in idiopathic pul-
monary fibrosis. Eur Respir J 2006;27:136e42.
[25] Tobin RW, Pope 2nd CE, Pellegrini CA, Emond MJ, Sillery J,
Raghu G. Increased prevalence of gastroesophageal reflux in
patients with idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med 1998;158:1804e8.
[26] Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal
hernia by blinded multidetector CT in patients with idio-
pathic pulmonary fibrosis. Eur Respir J 2012;39:344e51.
[27] Awadalla NJ, Hegazy A, Elmetwally RA, Wahby I. Occupa-
tional and environmental risk factors for idiopathic pulmo-
nary fibrosis in Egypt: a multicenter case-control study. Int J
Occup Environ Med 2012;3:107e16.
[28] Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic
pulmonary fibrosis. Epidemiologic approaches to occupa-
tional exposure. Am J Respir Crit Care Med 1994;150:670e5.
[29] Hubbard R, Lewis S, Richards K, Johnston I, Britton J.
Occupational exposure to metal or wood dust and aetiology
of cryptogenic fibrosing alveolitis. Lancet 1996;347:284e9.
[30] Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and
environmental factors and idiopathic pulmonary fibrosis in
Japan. Ann Occup Hyg 2005;49:259e65.
[31] Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of
sporadic and familial idiopathic pulmonary fibrosis: evidence
of founder effect among multiplex families in Finland. Tho-
rax 2002;57:338e42.
[32] Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata MR,
et al. Familial pulmonary fibrosis is the strongest risk factor
for idiopathic pulmonary fibrosis. Respir Med 2011;105:
1902e7.
[33] King Jr TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM.
Predicting survival in idiopathic pulmonary fibrosis: scoring
system and survival model. Am J Respir Crit Care Med 2001;
164:1171e81.
[34] Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary
fibrosis: impact of oxygen and colchicine, prednisone, or no
therapy on survival. Am J Respir Crit Care Med 2000;161:
1172e8.
[35] Cottin V, Cordier J-F. Subclinical interstitial lung disease:
no place for crackles? Am J Respir Crit Care Med 2012;186:
289.
[36] Cottin V, Cordier JF. Velcro crackles: the key for early
diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;
40:519e21.
[37] Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British
Thoracic Society study of cryptogenic fibrosing alveolitis:
current presentation and initial management. Fibrosing
Alveolitis Subcommittee of the Research Committee of the
British Thoracic Society. Thorax 1997;52:38e44.
[38] Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical sig-
nificance of circulating autoantibodies in idiopathic pulmo-
nary fibrosis. Respir Med 2013;107:249e55.
[39] Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are
an indicator of poor prognosis in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2009;179:588e94.
[40] Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of
circulating KL-6 in idiopathic pulmonary fibrosis. Respirology
2006;11:164e8.
[41] Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood
mononuclear cell gene expression profiles predict poor
outcome in idiopathic pulmonary fibrosis. Sci Transl Med
2013;5:205ra136.
[42] King Jr TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary
fibrosis: relationship between histopathologic features and
mortality. Am J Respir Crit Care Med 2001;164:1025e32.[43] Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary
fibrosis disease course from past trends in pulmonary func-
tion. Chest March 2014;145(3):579e85.
[44] Akagi T, Matsumoto T, Harada T, et al. Coexistent emphy-
sema delays the decrease of vital capacity in idiopathic
pulmonary fibrosis. Respir Med 2009;103:1209e15.
[45] Aduen JF, Zisman DA, Mobin SI, et al. Retrospective study of
pulmonary function tests in patients presenting with isolated
reduction in single-breath diffusion capacity: implications
for the diagnosis of combined obstructive and restrictive lung
disease. Mayo Clin Proc 2007;82:48e54.
[46] Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic
interstitial pneumonia: the prognostic value of longitudinal
functional trends. Am J Respir Crit Care Med 2003;168:
531e7.
[47] Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute
change in forced vital capacity in idiopathic pulmonary
fibrosis. Thorax 2012;67:407e11.
[48] Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in
forced vital capacity is associated with a poor outcome in
idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830e6.
[49] Collard HR, King Jr TE, Bartelson BB, Vourlekis JS,
Schwarz MI, Brown KK. Changes in clinical and physiologic
variables predict survival in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2003;168:538e42.
[50] du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test
in idiopathic pulmonary fibrosis: test validation and minimal
clinically important difference. Am J Respir Crit Care Med
2011;183:1231e7.
[51] Guerry-Force ML, Muller NL, Wright JL, et al. A comparison of
bronchiolitis obliterans with organizing pneumonia, usual
interstitial pneumonia, and small airways disease. Am Rev
Respir Dis 1987;135:705e12.
[52] Muller NL, Guerry-Force ML, Staples CA, et al. Differential
diagnosis of bronchiolitis obliterans with organizing pneu-
monia and usual interstitial pneumonia: clinical, functional,
and radiologic findings. Radiology 1987;162:151e6.
[53] Mathieson JR, Mayo JR, Staples CA, Muller NL. Chronic
diffuse infiltrative lung disease: comparison of diagnostic
accuracy of CT and chest radiography. Radiology 1989;171:
111e6.
[54] Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB.
Normal chest roentgenograms in chronic diffuse infiltrative
lung disease. N Engl J Med 1978;298:934e9.
[55] Sumikawa H, Johkoh T, Colby TV, et al. Computed tomog-
raphy findings in pathological usual interstitial pneumonia:
relationship to survival. Am J Respir Crit Care Med 2008;177:
433e9.
[56] Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological
versus histological diagnosis in UIP and NSIP: survival impli-
cations. Thorax 2003;58:143e8.
[57] Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE,
Godwin JD. The accuracy of the clinical diagnosis of new-
onset idiopathic pulmonary fibrosis and other interstitial
lung disease: a prospective study. Chest 1999;116:1168e74.
[58] Flaherty KR, Mumford JA, Murray S, et al. Prognostic impli-
cations of physiologic and radiographic changes in idiopathic
interstitial pneumonia. Am J Respir Crit Care Med 2003;168:
543e8.
[59] Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility
of a lung biopsy for the diagnosis of idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2001;164:193e6.
[60] ACR practice guideline for the performance of high-
resolution computed tomography (HRCT) of the lungs in
adults. at, http://www.acr.org/w/media/ACR/Documents/
PGTS/guidelines/HRCT_Lungs.pdf; 2010.
[61] Meyer KC, Raghu G, Baughman RP, et al. An official American
Thoracic Society clinical practice guideline: the clinical
828 J.M. Oldham, I. Nothutility of bronchoalveolar lavage cellular analysis in inter-
stitial lung disease. Am J Respir Crit Care Med 2012;185:
1004e14.
[62] Park JH, Kim DK, Kim DS, et al. Mortality and risk factors for
surgical lung biopsy in patients with idiopathic interstitial
pneumonia. Eur J Cardiothorac Surg 2007;31:1115e9.
[63] Utz JP, Ryu JH, Douglas WW, et al. High short-term mortality
following lung biopsy for usual interstitial pneumonia. Eur
Respir J 2001;17:175e9.
[64] Luo Q, Han Q, Chen X, Xie J, Wu L, Chen R. The diagnosis
efficacy and safety of video-assisted thoracoscopy surgery
(VATS) in undefined interstitial lung diseases: a retrospective
study. J Thorac Dis 2013;5:283e8.
[65] Flaherty KR, Travis WD, Colby TV, et al. Histopathologic
variability in usual and nonspecific interstitial pneumonias.
Am J Respir Crit Care Med 2001;164:1722e7.
[66] Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of
usual interstitial pneumonia and distinction from other
fibrosing interstitial lung diseases. Hum Pathol 2008;39:
1275e94.
[67] Flaherty KR, Toews GB, Travis WD, et al. Clinical significance
of histological classification of idiopathic interstitial pneu-
monia. Eur Respir J 2002;19:275e83.
[68] Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ.
Prednisone, azathioprine, and N-acetylcysteine for pulmo-
nary fibrosis. N Engl J Med 2012;366:1968e77.
[69] Visscher DW, Myers JL. Histologic spectrum of idiopathic
interstitial pneumonias. Proc Am Thorac Soc 2006;3:322e9.
[70] Flaherty KR, King Jr TE, Raghu G, et al. Idiopathic interstitial
pneumonia: what is the effect of a multidisciplinary
approach to diagnosis? Am J Respir Crit Care Med 2004;170:
904e10.
[71] Flaherty KR, Andrei AC, King Jr TE, et al. Idiopathic inter-
stitial pneumonia: do community and academic physicians
agree on diagnosis? Am J Respir Crit Care Med 2007;175:
1054e60.
[72] Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM,
Lederer DJ. Delayed access and survival in idiopathic pul-
monary fibrosis: a cohort study. Am J Respir Crit Care Med
2011;184:842e7.
[73] Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis
and malignancy. Curr Opin Pulm Med 2001;7:278e82.
[74] Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and
impact of coronary artery disease in idiopathic pulmonary
fibrosis. Respir Med 2010;104:1035e41.
[75] Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep
apnea is common in idiopathic pulmonary fibrosis. Chest
2009;136:772e8.
[76] Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary
fibrosis and emphysema: a distinct underrecognised entity.
Eur Respir J 2005;26:586e93.
[77] Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD.
Pulmonary hypertension in patients with pulmonary fibrosis
awaiting lung transplant. Eur Respir J 2007;30:715e21.
[78] Akhtar AA, Ali MA, Smith RP. Depression in patients with
idiopathic pulmonary fibrosis. Chron Respir Dis 2013;10:
127e33.
[79] Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux
therapy is associated with longer survival in patients with
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2011;184:1390e4.
[80] Mermigkis C, Bouloukaki I, Antoniou KM, et al. CPAP therapy
in patients with idiopathic pulmonary fibrosis and obstructive
sleep apnea: does it offer a better quality of life and sleep?
Sleep Breath 2013;17:1137e43.
[81] Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR,
Hunninghake GW. A controlled trial of sildenafil in advanced
idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620e8.[82] King Jr TE, Brown KK, Raghu G, et al. BUILD-3: a randomized,
controlled trial of bosentan in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2011;184:92e9.
[83] Continuous or nocturnal oxygen therapy in hypoxemic
chronic obstructive lung disease: a clinical trial. Nocturnal
Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391e8.
[84] Holland A, Hill C. Physical training for interstitial lung dis-
ease. Cochrane Database Syst Rev; 2008:CD006322.
[85] Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Pre-
dictors of benefit following pulmonary rehabilitation for
interstitial lung disease. Respir Med 2012;106:429e35.
[86] Nagai S, Kitaichi M, Hamada K, et al. Hospital-based histor-
ical cohort study of 234 histologically proven Japanese pa-
tients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:
209e14.
[87] Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in
idiopathic pulmonary fibrosis. N Engl J Med 2005;353:
2229e42.
[88] Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C.
Antioxidative and clinical effects of high-dose N-acetylcys-
teine in fibrosing alveolitis. Adjunctive therapy to mainte-
nance immunosuppression. Am J Respir Crit Care Med 1997;
156:1897e901.
[89] Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idio-
pathic pulmonary fibrosis. Eur Respir J 2010;35:821e9.
[90] Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in pa-
tients with idiopathic pulmonary fibrosis (CAPACITY): two
randomised trials. Lancet 2011;377:1760e9.
[91] Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-
controlled trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:
1040e7.
[92] Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents
for idiopathic pulmonary fibrosis. Cochrane Database Syst
Rev; 2010:CD003134.
[93] Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of
pirfenidone for the treatment of pulmonary fibrosis: a meta-
analysis of randomized controlled trials. PLoS One 2012;7:
e47024.
[94] Kubo H, Nakayama K, Yanai M, et al. Anticoagulant ther-
apy for idiopathic pulmonary fibrosis. Chest 2005;128:
1475e82.
[95] Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled
randomized trial of warfarin in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2012;186:88e95.
[96] Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin
on lung function and coagulation in healthy volunteers. Eur
Respir J 2002;19:606e10.
[97] Bendstrup E, Hilberg O. Is warfarin the right anticoagulant in
idiopathic pulmonary fibrosis? Am J Respir Crit Care Med
2012;186:693. author reply -4.
[98] Thabut G, Mal H, Castier Y, et al. Survival benefit of lung
transplantation for patients with idiopathic pulmonary
fibrosis. J Thorac Cardiovasc Surg 2003;126:469e75.
[99] Unilateral lung transplantation for pulmonary fibrosis.
Toronto Lung Transplant Group. N Engl J Med 1986;314:
1140e5.
[100] Organ Procurement and Transplantation Network (OPTN).
2012 at http://optn.transplant.hrsa.gov.
[101] Nathan SD, Shlobin OA, Ahmad S, Burton NA, Barnett SD,
Edwards E. Comparison of wait times and mortality for
idiopathic pulmonary fibrosis patients listed for single or
bilateral lung transplantation. J Heart Lung Transplant 2010;
29:1165e71.
[102] Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry
of the International Society for Heart and Lung Trans-
plantation: 29th adult lung and heart-lung transplant report-
2012. J Heart Lung Transplant 2012;31:1073e86.
Idiopathic pulmonary fibrosis 829[103] Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral
versus single-lung transplantation for idiopathic pulmonary
fibrosis. Ann Intern Med 2009;151:767e74.
[104] Mason DP, Brizzio ME, Alster JM, et al. Lung transplantation
for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007;84:
1121e8.
[105] De Oliveira NC, Osaki S, Maloney J, Cornwell RD, Meyer KC.
Lung transplant for interstitial lung disease: outcomes for
single versus bilateral lung transplantation. Interact Car-
diovasc Thorac Surg 2012;14:263e7.
[106] George TJ, Arnaoutakis GJ, Shah AS. Lung transplant in
idiopathic pulmonary fibrosis. Arch Surg 2011;146:1204e9.[107] Keating D, Levvey B, Kotsimbos T, et al. Lung transplantation
in pulmonary fibrosis: challenging early outcomes counter-
balanced by surprisingly good outcomes beyond 15 years.
Transplant Proc 2009;41:289e91.
[108] Orens JB, Estenne M, Arcasoy S, et al. International
guidelines for the selection of lung transplant candidates:
2006 updateea consensus report from the Pulmonary Sci-
entific Council of the International Society for Heart and
Lung Transplantation. J Heart Lung Transplant 2006;25:
745e55.
